Related Experiment Video
Updated: Jun 4, 2026
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Determinants of interferon β efficacy in patients with multiple sclerosis
Joep Killestein1, Chris H Polman
1Department of Neurology (MS Center Amsterdam), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. j.killestein@vumc.nl
Abstract:
Many patients with multiple sclerosis (MS) experience clinical relapses or progression of disability, or exhibit evidence of disease activity on MRI, despite the use of disease-modifying therapy. Although evidence clearly supports the efficacy of interferon β (IFN-β) in treating MS, the factors that determine the response to this drug in individual patients have not been fully elucidated. As more treatment options become available, the early identification of factors that can affect or predict the efficacy of agents in individual patients is important, because such knowledge facilitates early switching of treatment. Despite years of research and numerous reports of promising therapy markers for MS, few markers have emerged as clinically useful. Several studies suggest, however, that development of MRI lesions within 6-24 months after the initiation of IFN-β treatment predicts an unfavorable response. In addition, persistently high titers of neutralizing antibodies diminish or abrogate the therapeutic effects of IFN-β, and help to identify patients who do not respond. This Review highlights advances in research on the response to IFN-β in patients with MS and aims to provide a practical approach for incorporating clinical data, biological markers and MRI measures of disease activity into their therapeutic management.
Insights
Predicting multiple sclerosis (MS) treatment response is crucial. Early identification of non-responders to interferon beta (IFN-β) using MRI lesions and neutralizing antibodies allows for timely treatment adjustments.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacogenomics
Background:
- Multiple sclerosis (MS) patients often show disease activity despite treatment.
- Interferon beta (IFN-β) is effective, but individual patient response factors are unclear.
- Identifying predictors of IFN-β efficacy is vital for personalized MS management.
Purpose of the Study:
- To review current research on predicting response to interferon beta (IFN-β) in multiple sclerosis (MS).
- To offer a practical framework for integrating clinical, biological, and MRI data for therapeutic management.
- To guide early treatment adjustments for non-responding MS patients.
Main Methods:
- Review of existing studies on interferon beta (IFN-β) efficacy and response markers in multiple sclerosis (MS).
- Analysis of clinical data, biological markers (e.g., neutralizing antibodies), and MRI measures of disease activity.
- Synthesis of evidence to identify predictive factors for IFN-β treatment outcomes.
Main Results:
- Development of new MRI lesions within 6-24 months post-IFN-β initiation predicts poor response.
- Persistently high titers of neutralizing antibodies against IFN-β diminish therapeutic effects.
- Few reliable biomarkers have emerged, highlighting the need for integrated assessment.
Conclusions:
- Integrating clinical data, MRI findings, and antibody levels can improve prediction of IFN-β response in MS.
- Early identification of non-responders facilitates timely switching to alternative therapies.
- Personalized therapeutic strategies are essential for optimizing MS management.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:19Multiple Sclerosis l: Introduction